Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics (SE:IBT.B)
:IBT.B
RESEARCH TOOLSreports
Top Page
Infant Bacterial Therapeutics AB
(Berlin:IBT.B)
44Neutral
Infant Bacterial Therapeutics AB (IBT.B) vs. S&P 500 (SPY)
Market Cap
kr816.37M
Dividend YieldN/A
Average Volume (3M)28.11K
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue GrowthN/A
EPS Growth-2.51%
CountrySE
Employees8
SectorHealthcare
Sector Strength46
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.24
Shares Outstanding13,018,137
10 Day Avg. Volume22,211
30 Day Avg. Volume28,115
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-3.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Infant Bacterial Therapeutics AB Business Overview & Revenue Model
Company DescriptionInfant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
How the Company Makes MoneyInfant Bacterial Therapeutics AB generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered around licensing agreements, research and development collaborations, and eventual sales of its therapeutic products once they receive regulatory approval. Key revenue streams include upfront payments, milestone payments, and royalties from partners involved in the commercialization and distribution of its products. Significant partnerships with larger pharmaceutical companies or research institutions can also contribute to its earnings, providing access to additional resources and markets, which is crucial for advancing its product pipeline and achieving commercial success.
Infant Bacterial Therapeutics AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.00K | 77.00K | 12.00K | 0.00 | 0.00 | 0.00 | Gross Profit |
| 5.00K | 77.00K | 12.00K | 0.00 | 0.00 | -816.00K | EBIT |
| -145.34M | -134.62M | -65.81M | -44.58M | -71.92M | -47.20M | EBITDA |
| -136.09M | 11.55M | -65.45M | -44.99M | -72.01M | -45.50M | Net Income Common Stockholders |
| -136.91M | -123.07M | -65.09M | -45.40M | -72.31M | -47.05M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 540.51M | 329.06M | 335.84M | 386.75M | 423.44M | 495.19M | Total Assets |
| 561.03M | 351.33M | 349.62M | 408.48M | 450.32M | 518.27M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -540.51M | -329.06M | -335.84M | -386.75M | -423.44M | -495.19M | Total Liabilities |
| 5.00M | 46.18M | 17.91M | 13.22M | 10.16M | 7.88M | Stockholders Equity |
| 556.03M | 305.15M | 331.71M | 395.25M | 440.15M | 510.40M |
| Cash Flow | Free Cash Flow | ||||
| -121.69M | -101.22M | -85.80M | -55.62M | -58.39M | -51.30M | Operating Cash Flow |
| -121.69M | -101.22M | -85.80M | -55.62M | -58.39M | -51.30M | Investing Cash Flow |
| 0.00 | -4.15M | -1.00K | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 2.01M | 96.52M | 1.88M | 91.00K | 1.76M | 0.00 |
Infant Bacterial Therapeutics AB Technical Analysis
Positive
61.70
Price Trends
45.05
Positive
45.71
Positive
50.65
Positive
Market Momentum
4.60
Negative
63.49
Neutral
68.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 61.7 is above the 20-day moving average (MA) of 55.62, above the 50-day MA of 45.05, and above the 200-day MA of 50.65, indicating a bullish trend. The MACD of 4.60 indicates Negative momentum. The RSI at 63.49 is Neutral, neither overbought nor oversold. The STOCH value of 68.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.
Infant Bacterial Therapeutics AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | €1.12B | 5.10 | 179.17% | ― | 1887.36% | ― | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% | |
48 Neutral | kr922.35M | ― | -43.97% | ― | ― | 67.70% | |
47 Neutral | €1.09B | ― | -42.24% | ― | ― | -19.44% | |
44 Neutral | kr816.37M | ― | -57.38% | ― | ― | -2.51% | |
39 Underperform | €389.01M | ― | -194.31% | ― | 1643.36% | 50.36% | |
31 Underperform | €407.23M | ― | -111.62% | ― | ― | 46.67% |
* Healthcare Sector Average
Performance Comparison
SE:IBT.B
Infant Bacterial Therapeutics AB
60.60
-32.80
-35.12%
SE:CANTA
Cantargia AB
1.63
-2.02
-55.34%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.29
-8.31
-53.27%
SE:SANION
Saniona AB
8.00
6.20
344.44%
SE:XSPRAY
Xspray Pharma AB
32.10
-13.35
-29.38%
SE:SYNACT
SynAct Pharma AB
18.82
11.78
167.33%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.